Pharma News

Ministry of AYUSH introduced new Central Sector scheme for promoting Pharmacovigilance of AYUSH Drugs

  • Posted on: 20 February 2019
  • By: Shalini.Sharma

Ministry of AYUSH has introduced new Central Sector scheme for promoting pharmacovigilance of Ayurveda, Siddha, Unani and Homoeopathy (ASU&H) Drugs. Prime objective of the scheme is to develop the culture of documenting adverse effects and undertake safety monitoring of Ayurveda, Siddha, Unani and Homoeopathy drugs and surveillance of misleading advertisements appearing in the print and electronic media. The Standing Finance Committee (SFC) chaired by Secretary (AYUSH) approved the scheme on 1st November, 2017 and thereafter it was rolled out for implementation in the country near the end of financial year 2017-18.

Researchers find genetic vulnerability to menthol cigarette use

  • Posted on: 20 February 2019
  • By: Shalini.Sharma

A genetic variant found only in people of African descent significantly increases a smoker’s preference for cigarettes containing menthol, a flavor additive. The variant of the MRGPRX4 gene is five to eight times more frequent among smokers who use menthol cigarettes than other smokers, according to an international group of researchers supported by the U.S. Food and Drug Administration and the National Institutes of Health. The multiethnic study is the first to look across all genes to identify genetic vulnerability to menthol cigarettes. The paper was published online in the journal PLOS Genetics(link is external) on Feb. 15.

FDA new policy to improve access and foster price competition for drugs that face inadequate generic competition

  • Posted on: 16 February 2019
  • By: Shalini.Sharma

In too many cases, branded drugs that are no longer protected by patents or other exclusivities do not face expected competition. In fact, there are several hundred of such branded drugs that do not have any generic competition. Instances like these may keep prices high and ultimately hurt American patients.

FDA authorizes first interoperable insulin pump intended to allow patients to customize treatment through their individual diabetes management devices

  • Posted on: 15 February 2019
  • By: Shalini.Sharma

The U.S. Food and Drug Administration  permitted marketing of the Tandem Diabetes Care t:Slim X2 insulin pump with interoperable technology (interoperable t:Slim X2) for delivering insulin under the skin for children and adults with diabetes. This new type of insulin pump, referred to as an alternate controller enabled (ACE) infusion pump, or ACE insulin pump, is the first interoperable pump, meaning it can be used with different components that make up diabetes therapy systems, allowing patients to tailor their diabetes management to their individual device preferences. Diabetes therapy systems may be comprised of an ACE insulin pump and other compatible medical devices, including automated insulin dosing (AID) systems, continuous glucose monitors (CGMs), blood glucose meters or other electronic devices used for diabetes management.

NIH clinical trial to track outcomes of liver transplantation from HIV-positive donors to HIV-positive recipients

  • Posted on: 15 February 2019
  • By: Shalini.Sharma

The first large-scale clinical trial to study liver transplantation between people with HIV has begun at clinical centers across the United States. The HOPE in Action Multicenter Liver Study will determine the safety of this practice by evaluating liver recipients for potential transplant-related and HIV-related complications following surgery. The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and follows the 2018 launch of a similar study evaluating kidney transplantation between people with HIV.

FDA issues warning letter to doctor for illegally marketing unapproved device with claims to prevent and treat tightening of scar tissue around breast implants

  • Posted on: 15 February 2019
  • By: Shalini.Sharma

U.S. Food and Drug Administration issued a warning letter to Mark Berman, M.D., of Beverly Hills, California, for illegally marketing an unapproved implantable device, the Pocket Protector, that Dr. Berman claims can prevent and treat a complication of breast implants known as capsular contracture, or tightening of scar tissue. The warning letter also notifies Dr. Berman of significant deviations from the FDA’s quality system requirements and current good manufacturing practices (CGMPs), including deviations from manufacturing processes intended to keep implants sterile.

HITLAB Innovators Summit: India Assembles Leaders Across Healthcare Ecosystem to Bring Meaningful Innovation to Over a Billion Lives

  • Posted on: 14 February 2019
  • By: PharmaTutor News

Empowering meaningful digital health innovation for over a billion lives throughout India is the theme of the 2019 HITLAB Innovators Summit: India. The one-day event, sponsored by ANSYS, Praava Health, and Tech Care for All, will be held on February 16 at IIT Delhi, an Institute of Eminence. It brings together leaders and practitioners in life sciences, technology, academia, public health, medicine, investment, and design to leverage digital solutions and bring meaningful change to populations.

FDA ongoing efforts to stop the spread of illicit opioids, further secure the U.S. drug supply chain and forcefully confront opioid epidemic

  • Posted on: 14 February 2019
  • By: Shalini.Sharma

The opioid epidemic continues to be one of the greatest challenges facing this nation and the FDA.

On the illicit drugs front, worked to increase our enforcement and interdiction work targeting illegal, unapproved, counterfeit and potentially dangerous products being shipped illegally through international mail facilities (IMFs). Tens of millions of packages are estimated to contain FDA-regulated products, and a surprisingly high percentage of these products are illegal. In fact, in recent years, 86 percent of the packages that were suspected of containing FDA-regulated products and were pulled for FDA review indeed contained illegal, illicit, unapproved, counterfeit and/or potentially dangerous drugs.

NIH researchers home in on genes linked to age-related macular degeneration

  • Posted on: 14 February 2019
  • By: Shalini.Sharma

National Eye Institute scientists led a collaborative study and zeroed in on genes associated with age-related macular degeneration (AMD), a leading cause of vision loss and blindness among people age 65 and older. These findings provide a more expanded and in-depth picture of the genetic contributions to AMD, and they present new pathways for treatment development. The study was published Feb. 11 in Nature Genetics.

Pages